Shopping Cart
Remove All
Your shopping cart is currently empty
Vixtimotamab
😃Good
Catalog No. T80858
Alias TandAb T564, AMV-564
Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively targets human CD33 and CD3 antigens, and is used in acute myeloid leukemia (AML) research [1].
Vixtimotamab
Vixtimotamab
😃Good
Catalog No. T80858Alias TandAb T564, AMV-564
Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively targets human CD33 and CD3 antigens, and is used in acute myeloid leukemia (AML) research [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $747 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $1,930 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $2,970 | 2-4 weeks | 2-4 weeks |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively targets human CD33 and CD3 antigens, and is used in acute myeloid leukemia (AML) research [1]. |
| In vitro | Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC50 values of 1 pM and 2 pM, respectively [1]. Additionally, Vixtimotamab (TandAb T564; 4 days) promotes T-cell proliferation in PBMCs with an EC50 of 3 pM [1]. Furthermore, Vixtimotamab (TandAb T564; 25 pM, 48 h) exhibits cytotoxicity against HL-60 and KG-1a cells [1]. |
| In vivo | Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) demonstrated a dose-dependent delay in tumor growth in a prophylactic HL-60 xenografted NOD/scid mouse model [1]. Additionally, vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) significantly inhibited tumor growth in an established HL-60 xenografted NOD/scid mouse model [1]. |
| Synonyms | TandAb T564, AMV-564 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD33/CD3 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Vixtimotamab | purchase Vixtimotamab | Vixtimotamab cost | order Vixtimotamab | Vixtimotamab in vivo | Vixtimotamab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.